COVID antibody study for vulnerable kids halted early
NCT ID NCT04992273
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a single injection of two lab-made antibodies (casirivimab and imdevimab) in children under 12 who are at high risk for severe COVID-19. The goal was to see how the drug behaves in the body, if it is safe, and if it triggers an immune response. Only 7 children took part before the study was stopped early.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Advanced Research Center, Inc
Anaheim, California, 92805, United States
-
Batchelor's Children's Research Institute
Miami, Florida, 33136, United States
-
Coastal Pediatric Research
Charleston, South Carolina, 29414, United States
-
Jacobi Medical Center
The Bronx, New York, 10461, United States
-
Regeneron Research Site
Richmond, Virginia, 23226, United States
-
SUNY Upstate Medical University
Syracuse, New York, 13210, United States
-
Stony Brook University Hospital
Stony Brook, New York, 11794, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?